Tech Company Financing Transactions
Lung Therapeutics Funding Round
Lung Therapeutics, based in Austin, raised $36 million from Bios Partners.
Transaction Overview
Company Name
Announced On
6/10/2019
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series C
Investors
Bios Partners (Aaron Fletcher)
Proceeds Purpose
This financing will allow us to complete the first and only Phase II clinical trial in patients with Loculated Pleural Effusions, as well as a healthy volunteer Phase I clinical trial for our second product candidate, LTI-03, which is in development for IPF patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2600 Via Fortuna 360
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Website
Email Address
Overview
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Windsor
Chief Financial Officer
Charles Garner
Chief Scientific Officer
Steven Idell
Founder
Andrew Mazar
Browse more venture capital transactions:
Prev: 6/10/2019: Arsenal Medical venture capital transaction
Next: 6/10/2019: Platform venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs